FGP
PFE icon

Freestone Grove Partners’s Pfizer PFE Stock Holding History

Freestone Grove Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.08M Buy
335,530
+254,644
+315% +$6.66M 0.05% 309
2026
Q1 		$2.27M Sell
80,886
-968,995
-92% -$25.8M 0.02% 363
2025
Q4 		$26.1M Buy
+1,049,881
New +$26.5M 0.19% 174
2025
Q2 		– Sell
-31,287
Closed -$793K – 812
2025
Q1 		$793K Buy
31,287
+13,153
+73% +$344K 0.01% 364
2024
Q4 		$481K Buy
+18,134
New +$492K 0.01% 382

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Freestone Grove Partners's PFE Position: Q2 2026 in Review

Freestone Grove Partners increased its Pfizer (PFE) stake by 315% in Q2 2026, buying an estimated $6.66M and bringing the position to 335,530 shares worth $8.08M. The position accounts for 0.05% of the portfolio, ranked #309.

Freestone Grove Partners first reported a position in PFE in Q4 2024 and has held it in 5 quarters since. The position peaked at $26.1M in Q4 2025. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Freestone Grove Partners held 335,530 shares of Pfizer worth $8.08M as of Q2 2026.
  • Freestone Grove Partners bought 254,644 Pfizer shares in Q2 2026, an estimated $6.66M.
  • Pfizer made up 0.05% of Freestone Grove Partners's portfolio in Q2 2026, its #309 holding.
  • Freestone Grove Partners first reported a position in Pfizer in Q4 2024 and has held it in 5 quarters since.
  • Freestone Grove Partners's Pfizer position peaked at $26.1M in Q4 2025.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.